Search
Tofersen
go.drugbank.com/drugs/DB14782ApprovedInvestigational[L46133] In June of 2024, it was additionally approved by the EMA for the same indication. … [L52735] Tofersen demonstrated efficacy in reducing the concentration of SOD1 in CSF and of neurofilament light chains in plasma over 28 weeks, although the ALS Functional Rating Scale–Revised did not
Calcium polycarbophil
go.drugbank.com/drugs/DB14684ApprovedLess gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali. … is physiologically inert, and does not cause gastrointestinal irritation.
Sutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigational[L40114,A245144] Sutimlimab was also approved by the European Commission in November 2022.[L44116] … [A245144] Hemolysis in patients with CAD is driven by complement activation, which initiates a cascade that ultimately leads to both intra- and extravascular hemolysis.
Glecaprevir
go.drugbank.com/drugs/DB13879ApprovedInvestigationalMavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both [L940]. … Glecaprevir is available as an oral combination therapy with [DB13878] under the brand name Mavyret.
Alginic acid
go.drugbank.com/drugs/DB13518ApprovedInvestigationalWithdrawnIt is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46].
Mixtures: GAVISCON INFANT ORAL COZELTI ICIN TOZ ICEREN SASE, 30 ADET, GAVISCON INFANT ORAL COZELTI ICIN TOZ ICEREN SASE, 30 ADETSynonyms: (Alginate)n, (Alginate)n+1Fenoprofen
go.drugbank.com/drugs/DB00573ApprovedIt is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.
Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-NarcoticOrforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigational[L56122,L56123] It was the first new molecular entity approved under the Commissioner’s National Priority Voucher (CNPV) pilot program, achieving a regulatory decision just 50 days after filing. … Orforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist.
Selinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigationalOther chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant. … [L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant.
Levamlodipine
go.drugbank.com/drugs/DB09237ApprovedInvestigational[L1484] The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however. … [L10833] As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity.
EHT899
go.drugbank.com/drugs/DB05108ExperimentalEHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection.